Evidence that fibrinogen γ' regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans

Blood

Volumn 121, Issue 16, 2013, Pages 3254-3260

  Pieters, Marlien ^a   Kotze, Retha C ^a   Jerling, Johann C ^a   Kruger, Annamarie ^a   Ariëns, Robert A S ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; FIBRINOGEN GAMMA; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; FIBRIN; FIBRINOGEN GAMMA'; FIBRINOGEN VARIANT;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL STRUCTURE; CONCENTRATION PROCESS; EUGLOBULIN LYSIS TEST; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SOUTH AFRICAN; AGED; BLOOD; CHEMISTRY; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; NEGRO; REGRESSION ANALYSIS; SOUTH AFRICA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRINOGEN; FIBRINOGENS, ABNORMAL; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SOUTH AFRICA;

MLCS; MLOWN;

EID: 84879158179     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471482     Document Type: Article

References (34)

1. Francis CW, Marder VJ, Martin SE. Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem. 1980;255(12): 5599-5604.
2. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma’). Proc Natl Acad Sci USA. 1980;77(9):5069-5073.
3. Chung DW, Davie EW. gamma and gamma’ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry. 1984;23(18):4232-4236.
4. Fornace AJ Jr, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human gamma-fibrinogen gene. Alternate mRNA splicing near the 39 end of the gene produces gamma A and gamma B forms of gamma-fibrinogen. J Biol Chem. 1984;259(20):12826-12830.
5. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma’ levels. Blood. 2005; 106(13):4176-4183.
6. Drouet L, Paolucci F, Pasqualini N, et al. Plasma gamma’/gamma fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Blood Coagul Fibrinolysis. 1999;10(Suppl 1):S35-S39.
7. Lovely RS, Falls LA, Al-Mondhiry HA, Chambers CE, Sexton GJ, Ni H, Farrell DH. Association of gammaA/gamma’ fibrinogen levels and coronary artery disease. Thromb Haemost. 2002;88(1): 26-31.
8. Mannila MN, Lovely RS, Kazmierczak SC, et al. Elevated plasma fibrinogen gamma’ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost. 2007;5(4): 766-773.
9. Cheung EY, Uitte de Willige S, Vos HL, Leebeek FW, Dippel DW, Bertina RM, de Maat MP. Fibrinogen gamma’ in ischemic stroke: a case-control study. Stroke. 2008;39(3): 1033-1035.
10. van den Herik EG, Cheung EY, de Lau LM, et al. γ'/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost. 2011;105(3):430-434.
11. Uitte de Willige S, Standeven KF, Philippou H, Ariëns RA. The pleiotropic role of the fibrinogen gamma’ chain in hemostasis. Blood. 2009; 114(19):3994-4001.
12. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma’ alters fibrin formation and structure. Blood. 2003;102(2): 535-540.
13. Collet JP, Nagaswami C, Farrell DH, Montalescot G, Weisel JW. Influence of gamma’ fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol. 2004;24(2):382-386.
14. Siebenlist KR, Mosesson MW, Hernandez I, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma’ chains. Blood. 2005;106(8): 2730-2736.
15. Gersh KC, Nagaswami C, Weisel JW, Lord ST. The presence of gamma’ chain impairs fibrin polymerization. Thromb Res. 2009;124(3):356-363.
16. Allan P, Uitte de Willige S, Abou-Saleh RH, Connell SD, Ariëns RA. Evidence that fibrinogen γ' directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost. 2012;10(6): 1072-1080.
17. Lovely RS, Yang Q, Massaro JM, et al. Assessment of genetic determinants of the association of γ' fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol. 2011;31(10):2345-2352.
18. Alexander KS, Madden TE, Farrell DH. Association between γ' fibrinogen levels and inflammation. Thromb Haemost. 2011;105(4): 605-609.
19. van den Herik EG, Cheung EY, de Lau LM, et al. Fibrinogen γ' levels in patients with intracerebral hemorrhage. Thromb Res. 2012; 129(6):807-809.
20. Farrell DH. γ' Fibrinogen as a novel marker of thrombotic disease. Clin Chem Lab Med. 2012; 50(11):1903-1909.
21. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009;158(1):1-7, e1.
22. Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798): 1231-1243.
23. Pieters M, de Maat MP, Jerling JC, Hoekstra T, Kruger A. Fibrinogen concentration and its role in CVD risk in black South Africans—effect of urbanisation. Thromb Haemost. 2011;106(3): 448-456.
24. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3): 1102-1105.
25. Duckers C, Simioni P, Spiezia L, et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood. 2010;115(4): 879-886.
26. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
27. Pieters M, Vorster HH. Nutrition and hemostasis: a focus on urbanization in South Africa. Mol Nutr Food Res. 2008;52(1):164-172.
28. Carter AM, Cymbalista CM, Spector TD, Grant PJ; EuroCLOT Investigators. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007; 27(12):2783-2789.
29. Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood. 2008;111(10): 4854-4861.
30. Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J. 1992;63(1):111-128.
31. Falls LA, Farrell DH. Resistance of gammaA/ gamma’ fibrin clots to fibrinolysis. J Biol Chem. 1997;272(22):14251-14256.
32. Lovely RS, Kazmierczak SC, Massaro JM, D’Agostino RB Sr, O’Donnell CJ, Farrell DH. Gamma’ fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem. 2010;56(5): 781-788.
33. Mosesson MW, Hernandez I, Raife TJ, et al. Plasma fibrinogen gamma’ chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost. 2007;5(1):62-69.
34. Cheung EY, Vos HL, Kruip MJ, den Hertog HM, Jukema JW, de Maat MP. Elevated fibrinogen gamma’ ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood. 2009;114(20):4603-4604, author reply 4604-4605.